Libya vs Nauru: Statin use vs. average non-HDL cholesterol levels
Libya
3.1
in 2018
Nauru
3.1
in 2018
Libya rank
134th
Nauru rank
134th
Statin use vs. average non-HDL cholesterol levels over time
- Libya
- Nauru
How they compare
Libya currently reports 3.1 against 3.1 in Nauru, a difference of 0.
Across all 39 years both countries report, Nauru has been ahead every year.
Libya ranks 134th and Nauru ranks 134th of 191 countries.
Nauru has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Libya | Nauru | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.54 | 4.02 | 0.48 | Nauru |
| 1990s | 3.6 | 4.07 | 0.47 | Nauru |
| 2000s | 3.44 | 3.76 | 0.32 | Nauru |
| 2010s | 3.19 | 3.32 | 0.1333 | Nauru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Libya or Nauru?
- Libya, at 3.1 against 3.1 in Nauru as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Libya and Nauru?
- 0, with Libya ahead.
- How many years of comparable data are there for Libya and Nauru?
- 39 years are reported by both, from 1980 to 2018.
- How do Libya and Nauru rank globally for statin use vs. average non-hdl cholesterol levels?
- Libya ranks 134th and Nauru ranks 134th of 191 countries.
- Where does this data come from?
- World Health Organization – Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.